Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 1, 2014, Pages 2780-2789

  Chauvat, Anne ^a,b,c   Benhamouda, Nadine ^a   Gey, Alain ^a,b   Lemoine, Francois M ^d   Paulie, Staffan ^e   Carrat, Fabrice ^d,f,g   Gougeon, Marie Lise ^h   Rozenberg, Flore ⁱ   Krivine, Anne ⁱ   Cherai, Mustapha ^d   Lehmann, Paul V ^j   Quintin Colonna, Françoise ^a   Launay, Odile ^f,i,k   Tartour, Eric ^a,b,f,k  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c CTL Europe GmbH   (Germany)

^d SORBONNE UNIVERSITÉ   (France)

^e Mabtech AB   (Sweden)

^f INSERM   (France)

^g HÔPITAL SAINT ANTOINE   (France)

^h INSTITUT PASTEUR   (France)

ⁱ Institut Pasteur ^*  (France)

^j Cellular Technology Limited   (United States)

^k UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

FluoroSpot; IL 10 suppressive T cells; Immunomonitoring; Influenza vaccine; T cell response

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; GAMMA INTERFERON; INFLIXIMAB; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; MERCAPTOPURINE; METHOTREXATE;

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG MONITORING; ENZYME LINKED IMMUNOSPOT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY KIT; FLOW CYTOMETRY; FLUOROSPOT ASSAY; FLUOROSPOT ASSAY KIT; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOLOGY TEST KIT; INFLUENZA; INTERMETHOD COMPARISON; NONHUMAN; REGULATORY T LYMPHOCYTE; SENSITIVITY ANALYSIS; ULCERATIVE COLITIS; VALIDATION STUDY;

EID: 84896715675     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26593     Document Type: Article

References (72)

1. Tartour E, Mathiot C, Fridman WH. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother 1992; 46:473-84; PMID:1306361; http://dx.doi.org/10.1016/0753-3322(92)90005-R
2. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007; 13:175-82; PMID:17418641; http://dx.doi.org/10.1016/j.molmed.2007.03.004
3. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14:675-87; PMID:17875002
4. Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:17709554
5. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011; 118:4853-62; PMID:21908423; http://dx.doi.org/10.1182/ blood-2011-01-329656
6. De Carli M, D'Elios MM, Zancuoghi G, Romagnani S, Del Prete G. Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity. Autoimmunity 1994; 18:301-8; PMID:7858116; http://dx.doi.org/10. 3109/08916939409009532
7. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-98; PMID:19710487; http://dx.doi.org/10.1056/ NEJMra0707449
8. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332:65-8; PMID:21350122; http://dx.doi.org/10.1126/science.1200439
9. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MGA. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42; PMID:9338786; http://dx.doi.org/10.1038/39614
10. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2- inducing cytokines. J Exp Med 2002; 195:603- 16; PMID:11877483; http://dx.doi.org/10.1084/jem.20011629
11. Battaglia M, Stabilini A, Draghici E, Gregori S, Mocchetti C, Bonifacio E, Roncarolo MG. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55:40-9; PMID:16380475; http://dx.doi.org/10.2337/diabetes.55.01.06.db05- 0613
12. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421:388-92; PMID:12540904; http://dx.doi.org/10.1038/nature01315
13. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, Sharpe AH, Berry G, DeKruyff RH, Umetsu DT. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8:1024-32; PMID:12145647; http://dx.doi.org/10.1038/nm745
14. Cottrez F, Hurst SD, Coffman RL, Groux H. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000; 165:4848-53; PMID:11046008
15. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
16. Mascarell L, Lombardi V, Louise A, Saint-Lu N, Chabre H, Moussu H, Betbeder D, Balazuc AM, Van Overtvelt L, Moingeon P. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603-9, e5; PMID:18774396; http://dx.doi.org/10.1016/j.jaci.2008.06.034
17. Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC, et al. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol 2008; 180:3797-806; PMID:18322186
18. Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 2010; 71:1-11; PMID:20017804; http://dx.doi.org/10. 1111/j.1365-3083.2009.02321.x
19. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA. Intranasal immunization promotes th17 immune responses. J Immunol 2009; 183:6933- 8; PMID:19890060; http://dx.doi.org/10.4049/ jimmunol.0901144
20. Chauvat A, Benhamouda N, Loison E, Gougeon ML, Gey A, Levionnois E, Ravel P, Abitbol V, Roncelin S, Marcheteau E, et al. Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen. J Immunol Methods 2012; 378:81-7; PMID:22366633; http://dx.doi.org/10. 1016/j.jim.2012.02.008
21. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:18157017; http://dx.doi.org/10.1097/CJI. 0b013e318159f5ba
22. Haicheur N, Escudier B, Dorval T, Negrier S, De Mulder PH, Dupuy JM, Novick D, Guillot T, Wolf S, Pouillart P, et al. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol 2000; 119:28-37; PMID:10606961; http://dx.doi.org/10.1046/j.1365-2249. 2000.01112.x
23. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50; PMID:17558415; http://dx.doi.org/10.1038/nm1592
24. Peretz Y, Ndongala ML, Boulet S, Boulassel MR, Rouleau D, Côté P, Longpré D, Routy JP, Falutz J, Tremblay C, et al. Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression. Clin Immunol 2007; 124:57-68; PMID:17521962; http://dx.doi.org/10.1016/j.clim.2007.04.004
25. Gazagne A, Claret E, Wijdenes J, Yssel H, Bousquet F, Levy E, Vielh P, Scotte F, Goupil TL, Fridman WH, et al. A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods 2003; 283:91-8; PMID:14659902; http://dx.doi.org/10.1016/j.jim.2003.08.013
26. Rebhahn JA, Bishop C, Divekar AA, Jiminez-Garcia K, Kobie JJ, Lee FE, Maupin GM, Snyder-Cappione JE, Zaiss DM, Mosmann TR. Automated analysis of two- and three-color fluorescent Elispot (Fluorospot) assays for cytokine secretion. Comput Methods Programs Biomed 2008; 92:54-65; PMID:18644656; http://dx.doi.org/10.1016/j.cmpb.2008.06.002
27. McKinstry KK, Strutt TM, Swain SL. Hallmarks of CD4 T cell immunity against influenza. J Intern Med 2011; 269:507-18; PMID:21362069; http://dx.doi.org/10.1111/j.1365-2796.2011.02367.x
28. Karulin AY, Hesse MD, Tary-Lehmann M, Lehmann PV. Single-cytokine- producing CD4 memory cells predominate in type 1 and type 2 immunity. J Immunol 2000; 164:1862-72; PMID:10657635
29. Fujio K, Okamura T, Yamamoto K. The Family of IL-10-secreting CD4+ T cells. Adv Immunol 2010; 105:99-130; PMID:20510731; http://dx.doi.org/10.1016/ S0065-2776(10)05004-2
30. Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol 2011; 23:202-8; PMID:21840222; http://dx.doi.org/10. 1016/j.smim.2011.07.005
31. Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013; 19:739-46; PMID:23624599; http://dx.doi.org/10.1038/nm.3179
32. Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest 2006; 116:3252-7; PMID:17099776; http://dx.doi.org/10.1172/JCI29251
33. Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal Malefyt R, de Vries JE, Roncarolo MG. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179:493-502; PMID:7905018; http://dx.doi.org/10.1084/jem.179.2.493
34. Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, Duinkerken G, Pinkse GG, Keymeulen B, Roelen DL, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 2009; 9:382-8; PMID:19067657; http:// dx.doi.org/10.1111/j.1600-6143.2008.02479.x
35. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, Chin T, Kusaka S, Geissler F, Pelletier RP, Orosz CG. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106:145-55; PMID:10880058; http://dx.doi.org/ 10.1172/JCI9171
36. Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 2008; 68:3931-40; PMID:18483279; http://dx.doi.org/10.1158/0008-5472.CAN-07-5898
37. Nouri-Aria KT, Durham SR. Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets 2008; 7:237-52; PMID:19075789; http://dx.doi.org/ 10.2174/187152808786848405
38. Hallengärd D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, Bråve A. Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol 2011; 18:1577-81; PMID:21752954; http://dx.doi.org/10.1128/CVI.05045-11
39. Montero-Julian FA, Brailly H, Sautès C, Joyeux I, Dorval T, Mosseri V, Yasukawa K, Wijdenes J, Adler A, Gorin I, et al. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family. Clin Cancer Res 1997; 3:1443-51; PMID:9815830
40. Badoual C, Bouchaud G, Agueznay NelH, Mortier E, Hans S, Gey A, Fernani F, Peyrard S, -Puig PL, Bruneval P, et al. The soluble alpha chain of interleukin- 15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008; 68:3907-14; PMID:18483276; http://dx.doi.org/10.1158/0008-5472.CAN-07-6842
41. Guerkov RE, Targoni OS, Kreher CR, Boehm BO, Herrera MT, Tary-Lehmann M, Lehmann PV, Schwander SK. Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J Immunol Methods 2003; 279:111-21; PMID:12969552; http://dx.doi.org/10.1016/S0022-1759(03)00240-0
42. Tartour E, Mosseri V, Jouffroy T, Deneux L, Jaulerry C, Brunin F, Fridman WH, Rodriguez J. Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet 2001; 357:1263-4; PMID:11418153; http://dx.doi.org/10.1016/S0140-6736(00)04420-2
43. Ahlborg N, Axelsson B. Dual- and triplecolor fluorospot. Methods Mol Biol 2012; 792:77-85; PMID:21956502; http://dx.doi.org/10.1007/978-1-61779-325-7-6
44. Smedman C, Ernemar T, Gudmundsdotter L, Gille- Johnson P, Somell A, Nihlmark K, Gårdlund B, Andersson J, Paulie S. FluoroSpot analysis of TLRactivated monocytes reveals several distinct cytokine secreting subpopulations. Scand J Immunol 2011; 75:249-58; PMID:21955279; http://dx.doi.org/10.1111/j.1365-3083.2011.02641.x
45. Elrefaei M, McElroy MD, Preas CP, Hoh R, Deeks S, Martin J, Cao H. Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy. J Immunol 2004; 173:2184-9; PMID:15265956
46. Divekar AA, Zaiss DM, Lee FE, Liu D, Topham DJ, Sijts AJ, Mosmann TR. Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. J Immunol 2006; 176:1465-73; PMID:16424174
47. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009; 106:3877-82; PMID:19237568; http://dx.doi.org/10.1073/pnas.0813390106
48. Powers DC, McElhaney JE, Florendo OA Jr., Manning MC, Upshaw CM, Bentley DW, Wilkinson BE. Humoral and cellular immune responses following vaccination with purified recombinant hemag-glutinin from influenza A (H3N2) virus. J Infect Dis 1997; 175:342-51; PMID:9203655; http://dx.doi.org/10.1093/infdis/175.2.342
49. Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat 2011; 18:549-61; PMID:20626625; http://dx.doi.org/10. 1111/j.1365-2893.2010.01335.x
50. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194:1395-406; PMID:11714747; http://dx.doi.org/10.1084/jem.194.10. 1395
51. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58; PMID:18323851; http://dx.doi.org/10.1038/nri2274
52. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006; 211:236-54; PMID:16824132; http://dx.doi.org/10. 1111/j.0105-2896.2006.00395.x
53. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/10.1038/44385
54. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine- producing cells. J Virol 2007; 81:8468-76; PMID:17553885; http://dx.doi.org/10.1128/JVI.00228-07
55. Lucas M, Day CL, Wyer JR, Cunliffe SL, Loughry A, McMichael AJ, Klenerman P. Ex vivo phenotype and frequency of influenza virus-specific CD4 memory T cells. J Virol 2004; 78:7284-7; PMID:15194806; http://dx.doi.org/10.1128/JVI.78. 13.7284-7287.2004
56. Danke NA, Kwok WW. HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J Immunol 2003; 171:3163-9; PMID:12960344
57. Chapman TJ, Castrucci MR, Padrick RC, Bradley LM, Topham DJ. Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection. Virology 2005; 340:296-306; PMID:16054188; http://dx.doi.org/10.1016/j.virol.2005.06.023
58. Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, et al. Selective depletion of highavidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol 2007; 81:4199-214; PMID:17287271; http://dx.doi.org/10.1128/JVI.01388-06
59. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, Sekaly RP. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-22; PMID:14676302; http://dx.doi.org/10.1084/jem.20031598
60. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9:540-7; PMID:12692546; http://dx.doi.org/10.1038/nm866
61. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFNgamma/ IL-2-secreting CD8 T cells support CD4- independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 2005; 102:7239-44; PMID:15872023; http://dx.doi.org/10.1073/pnas.0502393102
62. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012; 206:158-66; PMID:22551811; http://dx.doi.org/10.1093/infdis/jis330
63. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413-24; PMID:16461338; http://dx.doi.org/10.1084/jem.20051720
64. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124:849-63; PMID:16497593; http://dx.doi.org/10.1016/j.cell.2006.02.019
65. Ndongala ML, Kamya P, Boulet S, Peretz Y, Rouleau D, Tremblay C, Leblanc R, Côté P, Baril JG, Thomas R, et al. Changes in function of HIV-specific T-cell responses with increasing time from infection. Viral Immunol 2010; 23:159-68; PMID:20373996; http://dx.doi.org/10.1089/vim.2009.0084
66. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77:4911-27; PMID:12663797; http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003
67. Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012; 30:1413-24; PMID:22197580; http://dx.doi.org/10.1016/j.vaccine.2011.11.109
68. Hillaire ML, Osterhaus AD, Rimmelzwaan GF. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011; 2011:939860; PMID:22007149; http://dx.doi.org/10.1155/2011/939860
69. Lee RS, Tartour E, van der Bruggen P, Vantomme V, Joyeux I, Goud B, Fridman WH, Johannes L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur J Immunol 1998; 28:2726-37; PMID:9754560; http://dx.doi.org/10.1002/(SICI)1521- 4141(199809)28:09〈2726::AIDIMMU2726〉3.0.CO;2-W
70. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, et al. Preexisting influenzaspecific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-80; PMID:22286307; http://dx.doi.org/10.1038/nm.2612
71. Gey A, Hamdi S, Vielh P, Mehtali M, Fridman WH, Tartour E. Development of a direct in situ RT-PCR method using labeled primers to detect cytokine mRNA inside cells. J Immunol Methods 1999; 227:149-60; PMID:10485262; http://dx.doi.org/10.1016/S0022-1759(99)00078-2
72. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105:1162-9; PMID:15479730; http://dx.doi.org/10. 1182/blood-2004-03-1211